Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1631 1692
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | Deciphera Pharmaceuticals, LLC |
| 18546245 | TREATING VIRAL INFECTION WITH NMD INHIBITORS | Non-Final OA | The Cleveland Clinic Foundation |
| 17759480 | BERBERINE COMPOUNDS, BERBERINE COMPOSITIONS, AND METHODS FOR ADMINISTRATION THEREOF | Final Rejection | Dignity Health |
| 18063841 | METHODS OF PRODUCING GLYCIDYL NITRATE AND RELATED SYSTEMS | Final Rejection | Northrop Grumman Systems Corporation |
| 18144990 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING OR ALLEVIATING GLIOMAS IN A SUBJECT | Non-Final OA | Zhejiang University |
| 18573074 | SULFOXIMINE COMPOUND AND USE THEREOF | Non-Final OA | USYNOVA PHARMACEUTICALS LTD. |
| 18573222 | SALT AND CRYSTAL FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | Non-Final OA | Blueprint Medicines Corporation |
| 18569414 | CRYSTALLINE FORMS OF ISOXAZOLINE COMPOUND | Non-Final OA | ELANCO US, INC. |
| 18569519 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Non-Final OA | Carrick Therapeutics Limited |
| 17921532 | DRUG COMBINATIONS FOR INHIBITING INFECTIVITY OF INFLUENZA AND CORONA VIRUSES | Final Rejection | SystaMedic Inc. |
| 18332851 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18549778 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Non-Final OA | Impact Therapeutics (Shanghai), Inc |
| 18546003 | 6-METHYLURACIL DERIVATIVES WITH ANTICHOLINESTERASE ACTIVITY AND THEIR USE | Non-Final OA | AVVA PHARMACEUTICALS LTD |
| 18020980 | DOSAGE FORM COMPOSITIONS COMPRISING AN INHIBITOR OF BTK AND MUTANTS THEREOF | Final Rejection | Newave Pharmaceutical Inc. |
| 18209515 | ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | Non-Final OA | SKINOSIVE |
| 18040824 | ATR INHIBITORS AND USES THEREOF | Non-Final OA | ANTENGENE DISCOVERY LIMITED |
| 17927073 | COMPOSITIONS OF CANNABINOIDS AND METHODS OF USING SAME | Non-Final OA | ASANA BIO GROUP LTD. |
| 17786912 | COMBINATION TREATMENTS FOR WALDENSTROM'S MACROGLOBULINEMIA | Final Rejection | X4 Pharmaceuticals, Inc. |
| 17755182 | USE OF B-CELL LYMPHOMA 2 (BCL-2) INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR TREATING CELLULAR SENESCENCE-RELATED SKIN DISEASES | Non-Final OA | Nanchang Anti-Senescence Biological & Medical Company |
| 17773404 | MrgprX2 Antagonists and Uses Thereof | Non-Final OA | Dermira, Inc. |
| 17769502 | DESLORATADINE FOR TREATMENT AND/OR PROPHYLACTIC TREATMENT OF GASTROINTESTINAL TRACT CANCERS | Final Rejection | Belina Pharma AB |
| 17760886 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | Non-Final OA | Step Pharma S.A.S. |
| 17581504 | PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS | Non-Final OA | TMEM16A LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy